



For personal use only

# Q3 2024 Earnings Presentation

November 7, 2024



# Forward-Looking Statements & Legal Disclaimers

This presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of clinical trials and other development activities; the uncertainties inherent in the initiation and enrollment of clinical trials; the unpredictability of the timing and results of regulatory submissions and reviews; market acceptance for approved products and innovative therapeutic treatments; competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. More information concerning AVITA Medical as well as the aforementioned risks and uncertainties is available in our public filings with the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2023, and other filings with the SEC. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise, except as required by law. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

AVITA Medical's products are Rx only. Please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events.

In the United States, RECELL® is approved for use in the treatment of thermal burn wounds and full-thickness skin defects and for repigmentation of stable depigmented vitiligo lesions. Use of RECELL in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited by United States law to investigational use only).



# Accelerating RECELL GO Account Conversions

For personal use only

Multiple devices maximize operating room efficiency



Burn injury between 10% - 20% TBSA

Enhanced features reduce training burden



Burn injury between 20% - 30% TBSA

Effectively treats large wounds



Burn injury between 50% - 60% TBSA


# BUILDING A BROAD-BASED WOUND CARE COMPANY

## RECELL at the Core of a Comprehensive Portfolio



For personal use only

### Continuum Of Burn And Full-thickness Skin Defect Wound Care




(1) Cohealyx is pending FDA clearance.

# Product Compatibility for Wound Care

## CLINICAL PRESENTATION: FULL-THICKNESS WOUND

For personal use only



**PermeaDerm by Stedical**

*Dressing optimized for protection and moisture management*

**RECELL + meshed split-thickness skin graft**

*Robust closure using significantly less skin compared to traditional grafting*

**Cohealyx<sup>1</sup>**

*Generation of vascularized tissue to support definitive closure*

**Wound bed preparation**  
*(actively exploring opportunities)*


*Delivers antimicrobial protection to maintain optimal healing environment*

(1) Cohealyx is pending FDA clearance.

# Quarterly Commercial Revenue

## STRONG COMMERCIAL GROWTH

For personal use only  
Commercial Revenue (in thousands)



(1) Represents the midpoint of commercial revenue guidance for Q4 2024.

For personal use only

*Transforming lives.*